Transformable liquid-metal nanomedicine.
Lu Y, Hu Q, Lin Y, Pacardo DB, Wang C, Sun W, Ligler FS, Dickey MD, Gu Z. · 2015
Read Transformable liquid-metal nanomedicine. by Lu Y, Hu Q, Lin Y, Pacardo DB, Wang C, Sun W, Ligler FS, Dickey MD, Gu Z. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4686762.txt.
Introduction
Yue Lu, Quanyin Hu, Yiliang Lin, and six colleagues built a drug carrier from liquid metal, reporting in Nature Communications in 2015. Hard inorganic particles can carry cancer drugs well, but they often linger in the body and raise toxicity worries. The team's answer was a soft sphere with a liquid gallium-indium core and a polymer shell. Sound waves were used to form the spheres, which came out small and easy to modify.
Loaded with the drug doxorubicin, the spheres held together until they reached mildly acidic spots inside cells, where they fused and broke down, freeing the drug. A targeting molecule helped them find tumors. In mice with tumors, the treatment slowed cancer growth more than controls. The design offers drug delivery that can change shape, do its job, and then degrade instead of persisting.
Catalog record
| CREATOR | Lu Y, Hu Q, Lin Y, Pacardo DB, Wang C, Sun W, Ligler FS, Dickey MD, Gu Z. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Transformable liquid-metal nanomedicine By Yue Lu, Quanyin Hu, Yiliang Lin, Dennis B Pacardo, Chao Wang, Wujin Sun, Frances S Ligler, Michael D Dickey, Zhen Gu Published in: Nature Communications DOI: 10.1038/ncomms10066 ABSTRACT Abstract To date, numerous inorganic nanocarriers have been explored for drug delivery systems (DDSs). However, the clinical application of inorganic formulations has often been hindered by their toxicity and failure to biodegrade. We describe here a transformable liquid-metal nanomedicine, based on a core–shell nanosphere composed of a liquid-phase eutectic gallium-indium core and a thiolated polymeric shell. This formulation can be simply produced through a sonication-mediated method with bioconjugation flexibility. The resulting nanoparticles loaded with doxorubicin (Dox) have an average diameter of 107 nm and demonstrate the capability to fuse and subsequently degrade under a mildly acidic condition, which facilitates release of Dox in acidic endosomes after cellular internalization. Equipped with hyaluronic acid, a tumour-targeting ligand, this formulation displays enhanced chemotherapeutic inhibition towards the xenograft tumour-bearing mice. This liquid metal-based DDS with fusible and degradable behaviour under physiological conditions provides a new strategy for engineering theranostic agents with low toxicity. The engineering flexibility provided by inorganic nanoparticles with tailorable shape, size, surface ligands and physical properties has enabled on-demand design of novel drug delivery systems, contrast agents and integrated systems for disease diagnosis and treatment1,2,3,4,5,6. The last decade has witnessed numerous efforts in developing inorganic nanoparticles capable of effectively targeting different diseases7,8,9,10,11. However, these formulations often fail to be useable due to systemic toxicity. For instance, targeted cancer therapy requires nanoparticles with relatively large sizes to minimize clearance12 and enhance tumour retention13,14, yet such inorganic particles often remain in the body for a long time because of their lack of biodegradability. To date, few studies have demonstrated how to engineer the physicochemical properties of inorganic nanoparticles to satisfy both target delivery and efficient elimination15,16. This design bottleneck has long existed and is impeding the clinical translation of therapy and diagnostics based on inorganic carriers. We report here a novel liquid metal-based nanoscale formulation for drug delivery to achieve enhanced anticancer therapy. Taking advantage of the unique characteristics of a eutectic alloy of gallium indium (EGaIn, 75% Ga and 25% In by weight), this novel nanomedicine has a variety of merits in terms of simple fabrication, facile surface bioconjugation and the capability of fusion and degradation in a mildly acidic environment. EGaIn is a low-viscosity liquid at room temperature. Unlike Hg, it has low toxicity and has thus attracted considerable attention for applications of microfluidic systems, soft robotics and stretchable electronics17,18,19. To obtain EGaIn-based drug nanocarriers, an emulsion-like ligand-mediated procedure is simply applied through ultrasonication at room temperature. During sonication20, the thiolated ligands readily assemble onto the surface of the EGaIn, competing with the oxidation process and facilitating control of the particle size17,20,21,22. The two ligands used here, thiolated (2-hydroxypropyl)-β-cyclodextrin (designated MUA-CD) and thiolated hyaluronic acid (designated m-HA), not only serve as capping agents during the formation of nanoscaled liquid-metal spheres but also play roles of drug-loading matrix and active targeting moiety, respectively. The final formulation (designated LM-NP/L) comprises three primary functional constituents: a CD-based drug-loading motif, the targeting ligand HA and an EGaIn core. The seven-membered sugar ring of the CD provides faithful loading sites for doxorubicin (Dox)23, a model broad-spectrum chemotherapeutic drug. The HA moiety supports active tumour targeting towards the receptors including the CD44 receptor, which is overexpressed on the cell surface of a broad variety of tumours, including human cervical cancer and breast cancer24. After intravenous injection, LM-NP/L is expected to accumulate at tumour sites as a result of passive25 and active targeting effects. Upon endocytosis, the LM-NPs/L are expected to fuse with each other in the mildly acidic endosome microenvironment26, leading to the dissociation of Dox-containing ligands and therefore promote drug release. The aggregates of fused LM-NPs/L are expected to degrade due to the synergistic effect of oxidative corrosion. Furthermore, the main degradation product, Ga (III), can serve as anticancer agent itself to reverse drug resistance in drug-resistant cancer cells27,28. Taken together, this liquid metal-based nanomedicine is transformable: (1) it can be simply generated from a bulk material; (2) fusion happens to promote drug release in an acidic cellular environment; and (3) it can be biodegraded to reverse drug resistance and avoid potential systemic toxicity. RESULTS Preparation of transformable liquid-metal nanomedicine To prepare the liquid metal nanocarriers, EGaIn was added to a centrifuge tube filled with an ethanolic solution of thiolate CD and thiolate HA (volume ratio of EGaIn: ethanol=1:150, Fig. 1a,b,e). After sonication, the largest particles precipitated within seconds, and the nanoscale colloids was removed from the tube and resuspended in water (Fig. 2a). Next, Dox-loaded LM-NP/L (LM-NP/Dox-L) was obtained by overnight incubation with triethanolamine-treated Dox. The mixture was washed to remove the excess Dox. The resulting LM-NP/Dox-L appeared as core–shell structured nanospheres with a diameter of ∼107 nm, which was consistent with the results determined by dynamic light scattering tests (Fig. 2b). The Dox-loading capacity could be tuned by adjusting the ratio between MUA-CD and m-HA. In a typical formulation used in the following investigations, the Dox-loading capacity was determined as 24% (Dox weight ratio of the total weight of nanoparticles). Interestingly, the addition of m-HA could significantly decrease the average particle size of product as well as enhance the systemic stability, which could be attributed to the negative charge of the anionic m-HA (Supplementary Table 1). [Figure: Schematic design of the transformable liquid-metal delivery system.(a) Preparation route of LM-NP/Dox-L. (b) The main components of LM-NP/Dox-L: thiolated CD with Dox, HA-based targeting motif and an EGaIn core. (c) pH-responsive delivery of Dox by LM-NP/Dox-L to the nuclei for the targeted cancer therapy. (I) accumulation of LM-NP/Dox-L at the tumour site through passive and active targeting; (II) specific binding to the overexpressed receptors on the tumour cells; (III) receptor-mediated endocytosis; (IV) acid-triggered fusion of LM-NP/Dox-L and endosomal/lysosomal escape of Dox-containing ligands; (V) accumulation of Dox in the nucleus. (d) Acid-triggered fusion and degradation process of LM-NP/Dox-L. (e) Chemical structures of MUA-CD and m-HA.] [Figure: Characterization of liquid-metal nanospheres.(a) EGaIn was ultrasonically dispersed in ligand containing ethanol mixture (shown schematically in Fig. 1a). (b) The hydrodynamic size of LM-NP/Dox-L measured by dynamic light scattering. Inset: TEM image of LM-NP/Dox-L. Scale bar, 100 nm. (c) The release profiles of LM-NP/Dox-L at different pH levels. (d) Representative TEM images of LM-NP/Dox-L after different time immersed in acidic (pH 5.0) PBS buffer. Scale bars, 100 nm (for 5 min); 100 nm (for 1 h); 100 nm (for 4 h); 400 nm (for 72 h). (e) Polydispersity index (PDI) of LM-NP/Dox-L immersed in neutral (pH 7.4) and acidic (pH 5.0) PBS buffer. (f) Changes of metal ion concentration under neutral and acidic environments. (g) Optical images of LM-NPs before and after acid treatment. Scale bar, 40 μm. (h) Light transmittance change over time. (i) X-ray images (left) of LM-NPs immersed in neutral (pH 7.4) and acidic (pH 5.0) PBS buffer (particles were imaged after 12 h treatment). The images were taken in a 96-well plate. Red lines indicate the areas quantitatively analysed. Grey value analysis (right) of representative area in X-ray images of LM-NPs. Error bars indicated s.d. (n=3).] To study the acid-triggered conformational transformation and subsequently promoted drug